Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on January 12th, 2016 by Christy J. WilsonPharma R&D
It’s the turn of the year and if you’re like me, you’ve been immersed in reading all of the accompanying look back and look ahead articles and reports. 2015 was, indeed, a notable year — from the Martin Shkreli fiasco to the proposed Pfizer and Allergan merger — the industry was rocked. (more…)
Posted on January 8th, 2016 by Christy J. WilsonPharma R&D
In early December, the New York Pharma Forum held its 26th Annual General Assembly, focusing on the theme “The Reinvention of Pharma,” and featuring executive-level speakers from Pfizer, Sunovion, Takeda, The Japan Pharmaceutical Manufacturers Association and the consulting company Defined Health to expound upon this theme. (more…)
Posted on January 7th, 2016 by Neal KatzPharmacovigilance
In December, Elsevier sponsored the 11th Annual Pharmacovigilance, Drug Safety and Risk Management conference in Brussels, Belgium and the 2nd Adverse Event Reporting and Safety Strategies Summit in Philadelphia, USA. (more…)
Posted on January 5th, 2016 by Joanna AldredChemistry
The best present I ever received as a child was a game called Mousetrap. For those unlucky enough not to have played this: releasing a lever leads to a series of seemingly random events, such as a boot kicking a ball, and finally to (more…)
Posted on December 18th, 2015 by Neal KatzPharma R&D
Technological advances in the retrieval and assessment of pathway and bioactivity data are giving rise to new in silico profiling and modeling methods. (more…)
Posted on December 16th, 2015 by Joyce de LangenPharmacovigilance
Limitations of clinical trials and traditional post-marketing sources of safety information.
Due to limitations of pre-marketing clinical trials, there isn’t much information available once a medicinal product is authorized for marketing. (more…)
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.